Shares of biopharmaceutical company Hookipa Pharma (NASDAQ:HOOK) are soaring today on the back of its licensing deal with Roche for HB-700 and a novel immunotherapy (undisclosed).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
With this move, Hookipa gains an upfront payment of $25 million, a potential optional payment of $15 million for another candidate as well as milestone payments of up to $930 million (apart from sales royalties).
Shares are now up ~24.4% over the last five days.
Read full Disclosure